<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031901</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-09-0259</org_study_id>
    <nct_id>NCT01031901</nct_id>
  </id_info>
  <brief_title>Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)</brief_title>
  <official_title>Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society for Pediatric Dermatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, double-blind, placebo-controlled evaluation of the
      safety of a topically applied formulation of rapamycin to cutaneous fibromatous lesions in
      subjects with Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1). Subjects will
      apply either a Polyvinylidene fluoride (PVDF) coating (Skincerity) containing rapamycin or
      the PVDF coating alone nightly to fibromatous lesions for a duration of six months.

      The primary goal of this study is to evaluate the safety of the topical product in patients
      with TSC and NF1. The secondary goal of this study is to evaluate the effectiveness of the
      topical product for treatment of cutaneous fibromatous lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rapamycin level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dermatologic sensitivity at site of application (pain, erythema, edema, pruritis)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in lesion size and appearance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Tuberous Sclerosis</condition>
  <condition>Neurofibromatoses</condition>
  <condition>Angiofibroma</condition>
  <condition>Neurofibroma</condition>
  <arm_group>
    <arm_group_label>TSC Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSC 1% Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSC 5% Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NF1 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NF1 1% Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NF1 5% Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skincerity</intervention_name>
    <description>Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas</description>
    <arm_group_label>TSC Placebo Arm</arm_group_label>
    <arm_group_label>NF1 Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skincerity plus sirolimus/rapamycin</intervention_name>
    <description>Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas</description>
    <arm_group_label>TSC 1% Arm</arm_group_label>
    <arm_group_label>NF1 1% Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skinercity plus sirolimus/rapamycin</intervention_name>
    <description>Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas</description>
    <arm_group_label>TSC 5% Arm</arm_group_label>
    <arm_group_label>NF1 5% Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is willing and able to comply with all trial requirements

          -  Subject is male or female and over 13 years of age

          -  Subject has a diagnosis of either TSC or NF1 and has visible fibromatous lesions
             (angiofibromas or neurofibromas)

          -  Female subjects of child-bearing potential must not be pregnant and must agree to use
             appropriate contraceptive methods for the duration of the trial

        Exclusion Criteria:

          -  Subject is currently receiving therapy with rapamycin or sirolimus

          -  Subject is receiving any form of immunosuppression or has previously experienced
             immune dysfunction

          -  Subject is currently participating in or has participated within the last 30 days in
             any clinical trial involving an investigational drug

          -  Subject has a known hypersensitivity to either the PVDF coating (SkincerityÂ®) or
             rapamycin

          -  Subject is a pregnant or nursing female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Kay Koenig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hope Northrup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.memorialhermann.org/locations/childrens/content.aspx?id=1048&amp;linkidentifier=id&amp;itemid=1048</url>
    <description>UT TSC Clinic Home</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>February 24, 2012</last_update_submitted>
  <last_update_submitted_qc>February 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Mary Kay Koenig</investigator_full_name>
    <investigator_title>Assistant Professor, Pediatrics-Neurology</investigator_title>
  </responsible_party>
  <keyword>Tuberous Sclerosis</keyword>
  <keyword>Neurofibromatoses</keyword>
  <keyword>Angiofibroma</keyword>
  <keyword>Neurofibroma</keyword>
  <keyword>Sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Angiofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

